1-(3,4-dichlorophenyl)-2-hydrazinoimidazoline hydroiodide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,4-dichlorophenyl)-2-hydrazinoimidazoline hydroiodide
• 英文别名: 1-(3,4-dichlorophenyl)-2-hydrazinylideneimidazolidine hydroiodide；[1-(3,4-Dichlorophenyl)-4,5-dihydroimidazol-2-yl]hydrazine;hydroiodide
• 化学式: C₉H₁₀Cl₂N₄*HI
• 分子量: 373.024
• InChiKey: GSTWTWFETHZKMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.25
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  53.6
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3,4-dichlorophenyl)-2-hydrazinoimidazoline hydroiodide 、 α-氧代-2-呋喃乙酸 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 正丁醇 为溶剂， 以63%的产率得到3-(2-furanyl)-8-(3,4-dichlorophenyl)-7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one
  参考文献：
  名称：

  新型3-（2-呋喃基）-8-芳基-7,8-二氢咪唑并[ 2,1- c ] [1,2,4]三嗪的合成，结构鉴定，亲脂性测定和体外抗肿瘤活性鉴定-4（6 H）-对正常人皮肤成纤维细胞具有低细胞毒性的

  摘要：

  十一新颖3-（2-呋喃基）-8-芳基-7,8-二氢咪唑并[2,1- c ^ ] [1,2,4]三嗪-4（6 ħ） -酮（12 - 22），设计并从适当的1-芳基-2- hydrazonoimidazolidines（获得1 - 11通过缩合反应与2-氧代-2-呋喃乙酸和中间链衍生物的随后环化缩合）。IR，1 H NMR和13 C NMR光谱及元素分析证实了所有合成化合物的化学结构。优化了反相HPLC方法，并证明了可用于分析这些未知小分子的可靠方法（12 – 22）。这些化合物在十八烷基硅胶（ODS）固定相上进行色谱分离，其疏水参数表示为log  k w值，通过RP-HPLC测定，使用甲醇和水的混合物作为流动相，并使用不同的甲醇浓度。将辛烷-1-磺酸钠盐（OSA-Na）和20％乙酸盐缓冲液（pH 3.5）添加至流动相（有机改性剂（MeOH）中含有0.01 M / L OSA-Na的洗脱液-缓冲流动相）。回归系数的高值（r>

  DOI：

  10.1016/j.bmc.2011.07.027
• 作为产物：
  描述：

  1-(3,4-Dichloro-phenyl)-2-methylsulfanyl-4,5-dihydro-1H-imidazole; hydriodide 在 一水合肼 作用下， 以 甲醇 为溶剂， 生成 1-(3,4-dichlorophenyl)-2-hydrazinoimidazoline hydroiodide
  参考文献：
  名称：

  两类新颖的融合的含氮杂胞嘧啶的同源物是有前途的候选药物：设计，合成以及体外，离体和计算机模拟研究。

  摘要：

  从医学的角度来看，寻找毒性较小的新抗癌药物候选药物是一个巨大的挑战。本研究旨在描述基于等距替代，光谱特征，新型分子的体外抗癌和离体抗溶血活性（9-22）以及其标准化亲脂性指数，计算对数平均值和药代动力学指标之间的相关性的两种独立的合成方法。首次开发了两种新颖的三嗪酮模板在肼基亚胺基咪唑烷（1-8）上反应的新方案（显示出对亲电子试剂的高反应活性，例如三氟丙酮酸乙酯和3-甲基-2-氧代丁酸乙酯），从而产生了两种原始类别的高度共轭的含氮杂胞嘧啶的分子（9-16和17-22）。两种合成均在碱性条件下进行，以产生最可能的中间体（例如，hememiaminals和亚胺），在两种情况下，通过回流双组分溶剂混合物或通过闭合功能化咪唑烷上的三嗪酮环使合适的溶剂环化。对所有融合的含氮杂异胞嘧啶的同源物进行了研究，目的是以更好的选择性预选可能的候选药物，以适合于更详细的药物开发研究。大多数测试分子​​在大多数肿

  DOI：

  10.1016/j.bioorg.2019.103480

文献信息

• Novel derivatives of methyl and ethyl 2-(4-oxo-8-aryl-2H-3,4,6,7-tetrahydroimidazo[2,1-c][1,2,4]triazin-3-yl)acetates from biologically active 1-aryl-2-hydrazinoimidazolines: Synthesis, crystal structure and antiproliferative activity
  作者：Krzysztof Sztanke、Jolanta Rzymowska、Maciej Niemczyk、Izabela Dybała、Anna E. Kozioł

  DOI：10.1016/j.ejmech.2006.06.013

  日期：2006.12

  respectively. Compound 2e revealed antibacterial activity against E. coli ATCC 25922, superior to ampicillin and inferior to chloramphenicol. Against S. aureus ATCC 25923 strain tested, compound 2e demonstrated MIC value inferior to ampicillin and chloramphenicol. Moreover, the synthesis, crystal structure and antiproliferative activity of novel derivatives of methyl and ethyl 2-(4-oxo-8-aryl-2H-3,4,6,7-tetrahydroimidazo[2

  通过与水合肼缩合反应，从合适的1-芳基-2-甲基硫代咪唑啉（1a-h）直接获得1-芳基-2-肼基咪唑啉（2a-h）。介绍了两个1-芳基-2-肼基咪唑啉（2b和2e）的抗​​菌活性。通过IR，（1）H NMR，EI-MS和元素分析证实了它们的化学结构。确定革兰氏阳性和革兰氏阴性细菌菌株，霉菌和酵母样真菌菌株对合成化合物的敏感性以及针对两种参考细菌菌株的MIC值。发现化合物2b相对于参考革兰氏阴性大肠杆菌ATCC 25922细菌菌株具有最强的抗菌活性，最小抑菌浓度（MIC）值为3.91micro g mL（-1）。化合物2b的活性（MIC）优于氨苄西林，与氯霉素相当。发现一种新型化合物2e分别对浓度为7.81micro g mL（-1）和15.62micro g mL（-1）的大肠杆菌ATCC 25922和金黄色葡萄球菌ATCC 25923有效。化合物2e表现出对大肠杆菌ATCC 25922的
• Crystal structure, antitumour and antimetastatic activities of disubstituted fused 1,2,4-triazinones
  作者：Krzysztof Sztanke、Kazimierz Pasternak、Małgorzata Sztanke、Martyna Kandefer-Szerszeń、Anna E. Kozioł、Izabela Dybała

  DOI：10.1016/j.bmcl.2009.07.036

  日期：2009.9

  4]triazin-4(6H)-ones (8–14) was confirmed by X-ray crystallography of 14. All the compounds were evaluated for their antitumour and antimetastatic activities in vitro. Furthermore, their cytotoxicities towards human normal cell line—HSF cells were established, allowing us to point out some structure–activity relationships. Among them, imidazotriazinone 12, revealing remarkable dose-dependent viability decreases in human

  的分子结构3,8-二取代的-7,8-二氢咪唑并[2,1- c ^ ] [1,2,4]三嗪-4（6 ħ） -酮（8 - 14）通过的X射线晶体学确认14。评估了所有化合物的体外抗肿瘤和抗转移活性。此外，还建立了它们对人类正常细胞系HSF细胞的细胞毒性，这使我们指出了一些结构与活性之间的关系。其中，咪唑三嗪酮12在人骨髓瘤RPMI 8226细胞中显示出显着的剂量依赖性生存力降低，被发现对正常HSF细胞完全无毒。此外，杂环自行车8 – 12 被证明在动力试验中显示出显着的抗转移潜力。
• Sztanke, Krzysztof, Acta poloniae pharmaceutica, 2004, vol. 61, # 5, p. 373 - 377
  作者：Sztanke, Krzysztof

  DOI：——

  日期：——
• Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold
  作者：Małgorzata Sztanke、Jolanta Rzymowska、Krzysztof Sztanke

  DOI：10.1016/j.bmc.2015.04.037

  日期：2015.7

  The straightforward and practical synthesis route and remarkable antitumour activities in vitro of a novel class of thiophene bioisosteres (10-18) are disclosed. These molecules were obtained with good overall yields via the reaction of 1-aryl-2-hydrazonoimidazolidine hydroiodides with ethyl 2-oxo-2-(2-thienyl) acetate in the presence of triethylamine in refluxing DMF/methanol mixture. All the synthesized compounds proved to be markedly effective against human tumour cells: A549, HeLa, T47D and TOV112D and more cytotoxic than pemetrexed against A549, HeLa and T47D cells. Among these strongly antiproliferative active molecules, the disclosed three thiophene bioisosteres (11, 17 and 18) are proposed as the most promising anticancer lead structures for the rational design of more selective antitumour agents because they proved to be markedly lower cytotoxic towards normal than tumour cells. Results from the bioassay based on a double fluorochrome staining were worthy to be described because they provide a clue to the mode of action of one (18) of the most promising anticancer lead structures of the series. (C) 2015 Elsevier Ltd. All rights reserved.
• Identification of antitumour activity of novel derivatives of 8-aryl-2,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazine-3,4-dione and 8-aryl-4-imino-2,3,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3(6H)-one
  作者：Krzysztof Sztanke、Kazimierz Pasternak、Jolanta Rzymowska、Małgorzata Sztanke、Martyna Kandefer-Szerszeń、Izabela Dybała、Anna E. Kozioł

  DOI：10.1016/j.bmc.2007.02.024

  日期：2007.4

  The series of 8-aryl-2,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazine-3,4-diones (11-20) and 8-aryl-4-imino-2,3,7,8-tetrahydroimidazo[2, I-c][1,2,4]triazin-3(6H)-ones (21-25) were designed and their in vitro cytotoxic activities against human LS180, HeLa, T47D, A549 and RPMI 8226 carcinoma cells are presented. In the crystalline state molecule 12 exists as the predominant tautomeric 3-oxo form. whereas the second possible 3-hydroxy tautomer is not observed. Compound 19 revealed a strong affection to LS180 cancer cells at lower tested concentration (37.9 mu M) and simultaneously was found to be non-toxic towards the normal cell line investigated-GMK cells. Furthermore, this compound was proved to possess the efficiency for DNA strand breakage of the examined cancer cell lines. However, imidazotriazin-3,4-dione 20 was able to cause significant viability decreases in human RPMI 8226 peripheral blood myeloma cells. Compound 22 has exhibited remarkable inhibitory effects against LS180 and A549 carcinoma cells, whereas 24 revealed the highest growth inhibition against A549 cell line. Simultaneously, at lower tested concentration these compounds were proved to be completely non-toxic for GMK cells. Moreover, cytotoxic and antibacterial properties of starting, tautomeric 1-aryl-2-hydrazonoimidazolidines (1-6 and 8-9) are presented. Six of them (1-2, 4-6 and 9) proved active as antimicrobials. All these compounds revealed MIC values in the range of 15.0-78.6 mu M. Their activities were compared to those of ampicillin and chloramphenicol. (c) 2007 Elsevier Ltd. All rights reserved.